Enhabit (EHAB) Q3 2025 Earnings Call Transcript

Enhabit raised full-year 2025 guidance to revenue $1.058–1.063B, adjusted EBITDA $106–109M and adjusted free cash flow $53–61M. Q3 consolidated revenue was $263.6M (+3.9% YoY) and adjusted EBITDA $27.0M (+10.2% YoY); Hospice drove outperformance with revenue $63.1M (+20% YoY) and adjusted EBITDA $17.2M (+72%, 27.3% margin). Home Health revenue was roughly flat at $200.5M (-0.2% YoY) with adjusted EBITDA down to $33.9M (−7.1% YoY) due to a payer renegotiation that compressed gross margins by ~160bps, though visits-per-episode fell to 13.4. Balance sheet improved: net debt/adjusted EBITDA 3.9x, available liquidity $143.3M, and $100M total debt reduction since Q4 2023.

Analysis

The company's playbook — a mix of payer renegotiation, high-margin hospice scale and operational levers around visit intensity — creates asymmetric optionality versus smaller regional peers. That combination both raises the floor (through cash generation and margin-rich hospice) and increases upside (through further rate resets with national payers and roll-out of efficiency pilots) if execution stays clean.

Primary downside remains regulatory: a materially worse-than-expected CMS final rule would compress unit economics faster than payers can reprice, and that risk is front-loaded into the next regulatory release window. Equally important is execution risk on clinical optimization — operational cuts that lower visits per episode can quickly attract quality/regulatory scrutiny and reverse payer goodwill, so cadence and documentation of clinical outcomes are critical near-term monitors.

Second-order winners include mid-sized consolidators and private-equity buyers of distressed independents: improved balance-sheet optionality makes the company both a likely acquirer and a more resilient competitor, pressuring smaller chains’ pricing and referral access. Labor pockets in therapy markets are a live watch — localized wage pressure could blunt unit-cost improvements even if national averages look comforting.

For traders, the near-term event calendar centers on the CMS final rule, subsequent payer re-contracting announcements and monthly census trajectories; these drive volatility and create discrete windows to add or hedge exposure. If the company continues to show durable cash conversion and de novo roll economics, expect the market to assign a higher multiple driven by consolidation optionality rather than pure organic growth.

Key Decisions for Investors

• Long EHAB equity (6–12 month hold): position to capture consolidation optionality and margin expansion if payer re-pricing continues. Risk/reward: target ~30–50% upside versus a 25–35% downside if CMS outcomes or clinical outcomes miss; use a 15–20% stop-loss to limit regime risk.
• Long EHAB Jan-2027 LEAP calls (or nearest 12–18 month call tenor): levered exposure to favorable payer resets and continued deleveraging. Risk/reward: limited premium loss if execution fails; potential 3–5x upside if hospice roll-up and payor wins materialize.
• Hedge trade for regulatory event (0–3 months): buy EHAB stock and simultaneously purchase 3–6 month protective puts to cap downside around the CMS final rule publication. Net: pay for optional protection to preserve upside from operational momentum while controlling event risk.
• Event-driven alert: add to positions on confirmed national payer renewals or on consistent month-over-month census recovery prints; if these catalysts fail to appear within two reporting cycles, trim exposure by 40–60%.